Bellerophon Therapeutics (BLPH) Financials

$0.01

$-0.04 (-77.86%)

As on 18-Dec-2024 12:51EDT

Market cap

$0 Mln

Revenue (TTM)

$6 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	5.64	5.64	--	--	--	--
Cost of Revenue	0.01	0.07	0.10	0.15	0.35	--
Gross Profit	5.63	-0.07	-0.10	-0.15	-0.35	--
Operating Expenses	16.68	22.38	20.16	26.28	17.47	27.88
Operating Profit (EBIT)	-11.04	-22.38	-20.16	-26.28	-17.47	-27.88
Other Income	0.07	--	--	-0.58	3.08	25.26
Profit before Tax	-10.53	-22.25	-19.56	-26.85	-15.07	-2.63
Provision for Tax	0.91	-2.42	-1.80	-2.13	-1.80	-5.44
Profit after Tax (Net Income)	-11.67	-19.83	-17.76	-24.73	-13.27	2.81
Minority Interest	--	--	--	--	--	--
Consolidated Profit	1.80	--	-17.76	-24.73	-13.27	2.81

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	3.72	2.53	21.62	38.25	3.59	3.86
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	1.43	0.20	1.56	1.93	6.97
Current Liabilities	1.26	5.40	5.05	10.43	7.58	7.54
Total Liabilities	6.24	7.94	26.88	50.24	13.11	18.36

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	--	0.37	1.42	2.16	2.73	0.96
Current Assets	4.98	7.56	25.46	48.08	10.38	17.40
Total Assets	6.24	7.94	26.88	50.24	13.11	18.36
Total Debt*	--	0.20	0.96	1.66	2.32	--
Net Current Assets	3.72	2.16	20.41	37.65	2.80	9.86

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-17.77	-22.82	-19.88	-12.94	-15.50
Cash Flow from Investing Activities	--	--	--	--	--	3.00
Cash from Financing Activities	--	-0.04	-0.01	57.57	6.17	0.17
Net Cash Inflow / Outflow	--	--	--	37.68	-6.77	-12.33

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-1.09	-2.08	-1.87	-2.61	-2.87	0.65
Cash EPS ($)	--	-2.07	-1.86	-2.59	-2.80	0.73
Adjusted Book Value ($)	--	0.27	2.27	4.03	0.78	0.89
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.86	-2.40	-2.09	-2.80	-3.57
Free Cash Flow per Share ($)	--	-1.86	-2.40	-2.09	-2.80	-3.57

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-156.70	-56.83	-107.94	-271.75	445.96
ROE (%)	-162.93	-164.21	-59.32	-118.20	-356.30	445.96
ROA (%)	-97.16	-113.94	-46.05	-78.07	-84.32	10.20
EBIT Margin (%)	-194.45	-394.47	--	--	--	--
Net Margin (%)	-204.52	-351.61	--	4,285.62	-430.89	11.14
Cash Profit Margin (%)	-0.03	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	49.16	-9.80	24.54	-78.21	71.44	-1,071.40
Net Profit Growth (%)	38.70	-11.69	28.19	-86.39	-571.46	105.13
EPS Growth (%)	45.44	-0.11	0.28	0.09	-5.44	1.04
Book Value Growth (%)	-60.89	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-0.43	-1.66	-2.56	-0.12	1.24
Price / Book Value	0.04	3.39	1.36	1.66	0.45	0.90
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-2.20	-0.07	-0.28	-0.65	0.40	0.25
Close Price ($)	0.40	0.90	3.10	6.67	5.25	12.02
High Price ($)	12.58	3.40	9.19	26.00	18.30	49.50
Low Price ($)	0.37	0.67	2.34	3.19	4.68	7.05
Market Cap ($ Cr)	0.15	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	0.08	0.04	0.04	0.65	--
Short term debt to equity ratio	--	0.08	0.07	0.04	0.37	--
Current Ratio	3.96	1.40	5.04	4.61	1.37	2.31
Quick Ratio	3.96	--	--	--	--	--
Interest Coverage	-6.36	-164.80	-4,052.60	-107.41	-2.96	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	0.47	0.32	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	6,804.89	8,803.60	8,486.47	3,075.76	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.